Key facts
- This page summarizes Thompson Bradley George's Form 4 filing for Enveric Biosciences, Inc. (ENVB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Sep 2021, 16:32.
Thompson Bradley George - 16 Sep 2021 Form 4 Insider Report for Enveric Biosciences, Inc. (ENVB)
- Reporting relationship
- Director
- Issuer ticker
- ENVB
- Reported as of
- 16 Sep 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Thompson Bradley George
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Thompson Bradley George filed Form 4 for Enveric Biosciences, Inc. (ENVB) on 27 Sep 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ENVB
transaction
Derivative
Stock Options
Award
- Transaction value
- Shares
- +53,160
- Change %
- Price
- Shares after
- 53,160
- Date
- 16 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 53,160
- Exercise price
- $0.9400
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.
Footnote F2
Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.
Footnote F3
Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.
Footnote F4
Received in exchange for options to acquire 200,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.